NBC Securities Inc. Lowers Stock Position in Johnson & Johnson (NYSE:JNJ)

NBC Securities Inc. cut its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 6.8% during the fourth quarter, HoldingsChannel reports. The firm owned 41,203 shares of the company’s stock after selling 3,009 shares during the period. Johnson & Johnson comprises about 0.7% of NBC Securities Inc.’s investment portfolio, making the stock its 18th biggest holding. NBC Securities Inc.’s holdings in Johnson & Johnson were worth $6,458,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in JNJ. 4J Wealth Management LLC raised its holdings in Johnson & Johnson by 2.2% during the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after purchasing an additional 62 shares in the last quarter. My Personal CFO LLC lifted its holdings in Johnson & Johnson by 1.4% in the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock valued at $713,000 after acquiring an additional 62 shares during the period. Eagle Strategies LLC boosted its position in shares of Johnson & Johnson by 1.8% during the 4th quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after purchasing an additional 63 shares in the last quarter. Clearview Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock valued at $685,000 after purchasing an additional 64 shares in the last quarter. Finally, Brookmont Capital Management lifted its stake in shares of Johnson & Johnson by 0.4% in the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock valued at $2,328,000 after purchasing an additional 64 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday, May 6th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Finally, Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $175.86.

Read Our Latest Report on JNJ

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

JNJ stock opened at $151.36 on Wednesday. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The company has a market cap of $364.28 billion, a price-to-earnings ratio of 9.44, a PEG ratio of 2.49 and a beta of 0.55. The business has a fifty day simple moving average of $152.63 and a 200-day simple moving average of $154.99. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same period last year, the business posted $2.68 EPS. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 10.64 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a $1.24 dividend. The ex-dividend date is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.28%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is presently 29.68%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.